EyePoint’s experimental drug Duravyu failed a late-stage trial for a serious eye disease. The company’s shares dropped significantly after the disappointing trial results were announced. This failure impacts EyePoint’s goal to compete with Regeneron’s successful Eylea treatment. Analysts suggest investors will await further study confirmation for the drug’s viability. EyePoint plans a new trial and FDA submission for approval in 2027.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.